Volume 115, Issue 9, September 2023

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

• Abstract
• View article

Partial breast irradiation compared with whole breast irradiation: a systematic review and meta-analysis

• Abstract
• View article
• Supplementary data

Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers

• Abstract
• View article
• Supplementary data

Effect of treatment interruptions on overall survival in patients with triple-negative breast cancer

• Abstract
• View article

Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer

• Abstract
• View article
• Supplementary data

Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools

• Abstract
• View article
• Supplementary data

Circulating proteome for pulmonary nodule malignancy

• Abstract
• View article
• Supplementary data

Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer

• Abstract
• View article

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

• Abstract
• View article

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials

• Abstract
• View article
• Supplementary data

Seamless phase II/III design: a useful strategy to reduce the sample size for dose optimization

• Abstract
• View article
• Supplementary data

Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation

• Abstract
• View article
• Supplementary data

Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic

• Abstract
• View article
• Supplementary data

Reviewers

• Extract
• View article